Key result
Postdischarge extended clinical pharmacist follow-up fails to reduce 90-day readmissions versus standard of care.
Why the study?
Data are limited regarding the effect of clinical pharmacist follow-up on 90-day readmissions and disease-specific clinical goals after hospitalization.
Does postdischarge extended clinical pharmacist follow-up reduce all-cause 90-day readmission rates in patients discharged from a family medicine service?
Cohort
Does postdischarge extended clinical pharmacist follow-up reduce all-cause 90-day readmission rates in patients discharged from a family medicine service?
Answers are grounded in this paper and cite their sources.
Postdischarge extended clinical pharmacist follow-up did not significantly reduce 90-day readmission rates, although it showed a significant reduction in 30-day readmissions.
Previous studies have shown pharmacists positively impact 30-day readmission rates. However, there is limited data regarding the effect of clinical pharmacist (CP) follow-up on 90-day readmission or evaluation of disease-specific goals after hospitalization. Investigators analyzed the impact of postdischarge extended CP follow-up within a family medicine service (FMS). The primary end point was all-cause 90-day readmission rates. Secondary end points included all-cause 30- and 60-day readmission rates and the achievement of disease-specific goals postdischarge. Retrospective chart review was performed for patients admitted from August 2016 to November 2017 who were seen by a physician within the FMS 14 days postdischarge. Fourteen percent of patients within the CP intervention group were readmitted within 90 days in comparison to 22% in the standard of care group ( P = .244). Readmission rates at 30 and 60 days were as follows: intervention group 2%, 10%, and standard of care group 16%, 22% ( P = .015, P = .089, respectively). In addition, multiple patients with uncontrolled diabetes who completed CP visits upon hospital discharge met glycemic goals at the end of the study time period. Despite inclusion of the CP in postdischarge care, 90-day readmission rate remained unchanged.
No takes yet. Share an insight, caveat, or question.
Wiegmann et al. (2019) conducted a cohort in Hospitalized patients discharged to a family medicine service. Postdischarge extended clinical pharmacist follow-up vs. Standard of care was evaluated on All-cause 90-day readmission rates (p=.244). Postdischarge extended clinical pharmacist follow-up did not reduce all-cause 90-day readmission rates compared to standard of care.
Synapse has enriched 10 related papers. Consider them for comparative context: